CA2368242A1 - Therapie combinee pour le traitement du glaucome - Google Patents

Therapie combinee pour le traitement du glaucome Download PDF

Info

Publication number
CA2368242A1
CA2368242A1 CA002368242A CA2368242A CA2368242A1 CA 2368242 A1 CA2368242 A1 CA 2368242A1 CA 002368242 A CA002368242 A CA 002368242A CA 2368242 A CA2368242 A CA 2368242A CA 2368242 A1 CA2368242 A1 CA 2368242A1
Authority
CA
Canada
Prior art keywords
iop
lowering agent
alkyl
glutamate
glutamate antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368242A
Other languages
English (en)
Inventor
Louis Desantis Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368242A1 publication Critical patent/CA2368242A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Méthodes permettant de traiter des personnes atteintes de glaucome ou d'hypertension oculaire à l'aide d'antagonistes de glutamate et de composés abaissant la pression intra-oculaire élevée.
CA002368242A 1999-03-12 1999-03-12 Therapie combinee pour le traitement du glaucome Abandoned CA2368242A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/005423 WO2000054810A1 (fr) 1999-03-12 1999-03-12 Therapie combinee pour le traitement du glaucome

Publications (1)

Publication Number Publication Date
CA2368242A1 true CA2368242A1 (fr) 2000-09-21

Family

ID=22272341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368242A Abandoned CA2368242A1 (fr) 1999-03-12 1999-03-12 Therapie combinee pour le traitement du glaucome

Country Status (5)

Country Link
EP (1) EP1169061A1 (fr)
AU (1) AU3082999A (fr)
CA (1) CA2368242A1 (fr)
HK (1) HK1040184A1 (fr)
WO (1) WO2000054810A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159266B1 (fr) 1999-03-05 2004-11-03 Duke University Analogues de prostaglandines c-16 fp selectives insaturees
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
JP2008507557A (ja) * 2004-07-22 2008-03-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 眼疾患の治療法
BRPI0513862A (pt) * 2004-07-26 2008-05-20 Allergan Inc métodos de tratar condições oftálmicas
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
SI3431074T1 (sl) 2010-07-29 2022-07-29 Allergan, Inc. Raztopine bimatoprosta in timolola brez konzervansov
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861079A1 (fr) * 1995-11-17 1998-09-02 Alcon Laboratories, Inc. Therapie combinee pour le traitement du glaucome

Also Published As

Publication number Publication date
WO2000054810A1 (fr) 2000-09-21
HK1040184A1 (zh) 2002-05-31
AU3082999A (en) 2000-10-04
EP1169061A1 (fr) 2002-01-09

Similar Documents

Publication Publication Date Title
US6441047B2 (en) Combination therapy for treating glaucoma
CA2368242A1 (fr) Therapie combinee pour le traitement du glaucome
US6271224B1 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
JP2007217437A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
AU704938B2 (en) Combination therapy for treating glaucoma
US6264935B1 (en) Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum
AU6057199A (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
EP0672417A1 (fr) Réduction de la pression intra-oculaire
EP1267847B1 (fr) Agonistes de 5ht 2 permettant de controler la pression intra-oculaire elevee et de traiter le glaucome
US6200990B1 (en) Neuroprotective agents having antioxidant and NMDA antagonist activity
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
EP1647274A1 (fr) Remede contre le prurit comprenant un derive de piperidine comme principe actif
EP3730137B1 (fr) Agent thérapeutique du glaucome comprenant un agoniste fp et timolol
AU2004214563A1 (en) Combination therapy for treating glaucoma
US5308849A (en) Method of reducing elevated intraocular pressure
AU2001217709B2 (en) Combination therapy for lowering and controlling intraocular pressure
EP0728480A1 (fr) Utilisation d'ifenprodil pour le traitement de la pression intraoculaire élevée
US6927233B1 (en) 5ht2 agonists for controlling IOP and treating glaucoma
AU2001217709A1 (en) Combination therapy for lowering and controlling intraocular pressure
EP0277814B1 (fr) Utilisation de trifluorométhanesulfonamide contre le glaucome
US20180118676A1 (en) Nitric oxide donating derivatives of latanoprost free acid
AU716577B2 (en) Use of polyamine antagonists for the treatment of glaucoma
EP0607697A2 (fr) DILAZEP pour la réduction de la pression intraoculaire élevée
US20040058976A1 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead